In 2022, Donor Governments Spent US$8.2 billion on Efforts to Fight HIV/AIDS Globally, Returning to 2020 Funding Levels and Still Below the High-water Mark of Almost a Decade Ago July 13, 2023 News Release A new report from KFF and The Joint United Nations Programme on HIV/AIDS (UNAIDS) reveals that donor governments disbursed US$8.2 billion in 2022 to combat HIV in low- and middle-income countries, returning to 2020 funding levels and still below the high-water mark of $8.6 billion in 2014. The funding supports…
Donor Government Funding for HIV in Low- and Middle-Income Countries in 2022 July 13, 2023 Report This report tracks funding levels of the donor governments that collectively provide the bulk of international assistance for AIDS through bilateral programs and contributions to multilateral organizations. Overall, the analysis shows that while donor government funding for HIV increased between 2021 and 2022, this was primarily due to the timing of payments from the U.S. government and not actual increases in commitments.
10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year July 12, 2023 News Release A new KFF analysis finds that the 10 top-selling prescription drugs under Medicare Part D comprised less than 1 percent of all covered drugs in 2021, but accounted for 22 percent, or $48 billion, of gross Medicare Part D drug spending that year. The analysis provides context for understanding the…
A Small Number of Drugs Account for a Large Share of Medicare Part D Spending July 12, 2023 Issue Brief The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
New KFF Analysis Examines Rapidly Evolving Federal Policies For Substance Use Disorder Treatment for the Opioid Epidemic July 11, 2023 News Release A new KFF analysis finds that 24 percent more buprenorphine, a medication to treat opioid use disorder, was dispensed in 2022 than in 2019, the year before the pandemic brought a surge of opioid overdose deaths – and a focus on how to expand access and treatment. This upward trend…
Addressing the Opioid Crisis: A Look at the Evolving Landscape of Federal OUD Treatment Policies July 11, 2023 Issue Brief Federal policies governing substance use disorder treatment have undergone rapid changes during the pandemic; however, the extent to which these changes can address the surge in opioid overdose deaths is unclear. Some of these policy adjustments are permanent, while others could revert to pre-pandemic regulations. In this brief, we examine the following 5 key federal policies and implications for access and treatment for OUD.
Overview of Health Coverage and Care for Individuals with Limited English Proficiency (LEP) July 7, 2023 Issue Brief This brief analyzes 2021 American Community Survey data to highlight demographic, socioeconomic , and health coverage characteristics of individuals with limited English proficiency (LEP).
New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare July 6, 2023 Blog The Food and Drug Administration granted full approval to Leqembi, a new Alzheimer’s drug, on July 6, 2023. This updated policy watch focuses on the implications of Medicare coverage of the drug for program spending as well as equity and affordability issues for beneficiaries, and the potential for the Inflation Reduction Act to address the spending impacts. It also covers additional details from the Centers for Medicare and Medicaid Services about patient registries.